6-MBPB

6-MBPB, also known as 6-(2-methylaminobutyl)benzofuran (6-MABB), is a monoamine releasing agent (MRA) and entactogen-like drug of the amphetamine, phenylisobutylamine, and benzofuran families. It is a positional isomer of 5-MBPB (5-MABB).

The drug appears to act as a serotonin-norepinephrine-dopamine releasing agent (SNDRA). The EC₅₀Tooltip half-maximal effective concentration values for induction of monoamine release in rat brain synaptosomes have been reported for the individual enantiomers of 6-MBPB. In the case of (S)-6-MBPB, they were 54 nM for serotonin, 77 nM for norepinephrine, and 41 nM for dopamine, whereas for (R)-6-MBPB, they were 172 nM for serotonin, 227 nM for norepinephrine, and inactive for dopamine. Hence, (S)-6-MBPB is an SNDRA, whereas (R)-MBPB is a serotonin-norepinephrine releasing agent (SNRA). The enantiomers showed a mixed profile of acting as full versus partial releasers. Unlike 5-MAPB, it is a relatively weak serotonin 5-HT_1B receptor agonist. 6-MBPB partially substituted for MDMA in animal drug discrimination tests at lower doses and fully substituted for MDMA at the highest dose, suggesting that it has entactogen-like effects.

Along with 5-MBPB, 6-MBPB was patented by Matthew Baggott and Tactogen in 2021. It was first described in the scientific literature by 2022. 6-MBPB, along with other drugs like 5-MBPB, is being investigated as a novel MDMA-like drug for potential therapeutic purposes in medicine.